Pharmaxis Research Programs Highlighted at European Respiratory Society Congress
03 Ottobre 2008 - 2:26AM
PR Newswire (US)
SYDNEY, Australia, Oct. 3 /Xinhua-PRNewswire-FirstCall/ --
Pharmaceutical company Pharmaxis (ASX:PXSASX:NASDAQ:ASX:PXSL) has
announced that researchers will present 12 abstracts from its
respiratory disease program at the 2008 European Respiratory
Society Congress (ERS) being held in Berlin from the 4th to the 8th
October. The ERS brings together many of the world's top
respiratory researchers and clinicians to hear latest advances in
clinical diagnosis and treatment. A comprehensive program of
research will be presented in ERS symposiums and poster sessions
relating to the lung challenge product, Aridol, and the mucus
clearing agent, Bronchitol. In a poster session Professor Di
Bilton, Consultant Physician and Honorary Senior Lecturer at the
Department of Respiratory Medicine, The Royal Brompton Hospital,
London, UK, will detail results of a successful randomized,
placebo- controlled trial of inhaled mannitol (Bronchitol) in
patients with bronchiectasis. Other key ERS program events from the
Pharmaxis respiratory disease program include: -- The use of
inhaled mannitol (Aridol) for assessing airway disease -- Direct
versus indirect airway challenges -- Using a dry powder of mannitol
(Aridol) versus methacholine as challenge for routine practice --
Inhaled mannitol (Bronchitol) as treatment for children with cystic
fibrosis -- Implications for everyday practice -- Infectious lung
diseases including tuberculosis -- A randomized, placebo-controlled
trial of inhaled mannitol(Bronchitol) in patients with
bronchiectasis -- Cough and airway hyperresponsiveness -- A
comparison of inhaled mannitol (Aridol), methacholine provocation
and eucapnic voluntary hyperventilation as diagnostic tests for
exercised-induced bronchoconstriction in cross country skiers --
Assessment of inflammation, hyperresponsiveness and response to
exercise in asthmatic children -- Mannitol dry powder challenge
(Aridol) in comparison with exercise testing and methacholine
challenge test in children -- Responsiveness to mannitol (Aridol)
and exercise challenge in children with asthma -- Association
between mannitol dry powder challenge (Aridol) test results and
fractional exhaled nitric oxide in children -- Exercise-induced
asthma, acute severe asthma and allergic rhinitis in children --
Change of exercise challenge tests and mannitol challenge test
(Aridol) during optimized asthma treatment in adolescents with
exercise induced asthma -- Investigation, inspiration, ventilation,
dedication: the essence of physiological measurement -- The
perception of breathlessness during bronchoconstriction induced by
mannitol (Aridol) in COPD -- Phenotyping of asthma and COPD --
Airway hyperresponsiveness to mannitol (Aridol) and exhaled NO are
related to inflammatory subtypes in asthma. ERS is Europe's biggest
annual scientific gathering in respiratory medicine, with more than
17,000 participants each year. It aims to provide a platform for
important improvements in the treatment of lung diseases. Full
details of ERS may be viewed on the ERS website at
http://dev.ersnet.org/415-general-information.htm SOURCE: Pharmaxis
Ltd, Sydney, Australia CONTACT: Alan Robertson - Chief Executive
Officer Ph: +61 2 9454 7200 or email RELEASED THROUGH: Australia:
Felicity Moffatt, phone +61 418 677 701 or email United States:
Brandon Lewis, Trout Group, phone +1 646 378 2915 or email
Forward-Looking Statements The statements contained in this media
release that are not purely historical are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended. Forward-looking statements in
this media release include statements regarding our expectations,
beliefs, hopes, goals, intentions, initiatives or strategies,
including statements regarding the potential for Aridol and/or
Bronchitol. All forward-looking statements included in this media
release are based upon information available to us as of the date
hereof, and we assume no obligation to update any such
forward-looking statement as a result of new information, future
events or otherwise. We can not guarantee that any product
candidate will receive FDA or other regulatory approval or that we
will seek any such approval. Factors that could cause or contribute
to such differences include, but are not limited to, factors
discussed in the "Risk Factors and Other Uncertainties" section of
our Form 20-F lodged with the U.S. Securities and Exchange
Commission. DATASOURCE: Pharmaxis Contact: Alan Robertson, Chief
Executive Officer, +61 2 9454 7200, , or Felicity Moffatt, +61 418
677 701,
Copyright